Oxidative status and serum PON1 activity in beta-thalassemia minor

Clinical Biochemistry

Volumn 40, Issue 5-6, 2007, Pages 287-291

  Selek, Sahbettin ^a   Aslan, Mehmet ^a   Horoz, Mehmet ^a   Gur, Mustafa ^a   Erel, Ozcan ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Beta thalassemia minor; Oxidative stress; PON1; Total antioxidant capacity

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; LIPID HYDROPEROXIDE;

ADULT; ARTICLE; ATHEROGENESIS; BETA THALASSEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME METABOLISM; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BETA-THALASSEMIA; CARBOXYLIC ESTER HYDROLASES; FEMALE; HUMANS; LIPID PEROXIDES; LIPIDS; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 33847223747     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.10.028     Document Type: Article

References (29)

1. Vigi V., Volpato S., Gaburro D., Conconi F., Bargellesi A., and Pontremoli S. The correlation between red-cell survival and excess of alpha-globin synthesis in b-thalassemia. Br. J. Haematol. 16 (1969) 25-30
2. Tesoriere L., Arpa D., Moggio A., Giaccone V., Pedone E., and Livrea M.A. Oxidation resistance of LDL is correlated with vitamin E status in beta-thalassemia intermedia. Atheroseclerosis 137 (1998) 429-435
3. Steinberg D., Parthasaraty S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modification of low density lipoprotein that increase atherogenicity. N. Engl. J. Med. 320 (1989) 915-924
4. Berliner J.A., and Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20 (1996) 707-727
5. Blatter M.C., James R.W., Messmer S., Barja F., and Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur. J. Biochem. 211 (1993) 871-879
6. Canales A., and Sanchez-Muniz F.J. Paraoxanase, something more than an enzyme?. Med. Clin. (Barc.) 121 (2003) 537-548
7. Chakraborty D., and Bhattacharyya M. Antioxidant defense status of red blood cells of patients with b-thalassemia and Ebeta-thalassemia. Clin. Chim. Acta 305 (2001) 123-129
8. Kassab-Chekir A., Laradi S., Ferchichi S., HajKhelil A., Feki M., Amri F., et al. Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin. Chim. Acta 338 (2003) 79-86
9. Dhawan V., Kumar K.H.R., Marwaha R.K., and Ganguly N.R. Antioxidant status in children with homozygous beta thalassemia. Indian Pediatr. 42 (2005) 1141-1145
10. Livrea M.A., Tesoriere L., Maggio A., D'Arpa D., Pintaudi A.M., and Pedone E. Oxidative modification of low-density lipoprotein and atherogenetic risk in beta-thalassemia. Blood 92 (1998) 3936-3942
11. Calandra S., Bertolini S., Pes G.M., Deiana L., Tarugi P., Pisciotta L., et al. Beta-thalassemia is a modifying factor of the clinical expression of familial hypercholesterolemia. Semin. Vasc. Med. 4 (2004) 271-278
12. Brizzi P., Isaja T., D'Agata A., Malaguarnera L., Malaguarnera M., and Musumeci S. Oxidized LDL antibodies (OLAB) in patients with beta-thalassemia major. J. Atheroscler. Thromb. 9 (2002) 139-144
13. Morales N.P., Charlermchoung C., Luechapudiporn R., Yamanont P., Fucharoen S., and Chantharaksri U. Lipid fluidity at different regions in LDL and HDL of beta-thalassemia/Hb E patients. Biochem Biophys Res. Commun. (2006 (Sep. 28)) 10.1016/j.bbrc.2006.09.106
14. Vives Corrons J.L., Miguel-Garcia A., Pujades M.A., Miguel-Sosa A., Cambiazzo S., Linares M., et al. Increased susceptibility of microcytic red blood cells to in vitro oxidative stress. Eur. J. Haematol. 55 (1995) 327-331
15. Tassiopoulos S., Deftereos S., Konstantopoulos K., Farmakis D., Tsironi M., Kyriakidis M., et al. Does heterozygous beta-thalassemia confer a protection against coronary artery disease?. Ann. N. Y. Acad. Sci. 1054 (2005) 467-470
16. Weatherall D.J. The thalassaemias. In: Beutler E., Lichtman M.A., Coller B.S., and Kipps T.J. (Eds). Williams hematology (1995), McGraw-hill, New York 581-615
17. Sodergren E., NouroozZadeh J., Berglund L., and Vessby B. Re-evaluation of the ferrous oxidation in xylenol orange assay for the measurement of plasma lipid hydroperoxides. J. Biochem. Biophys. Methods 37 (1998) 137-146
18. Eckerson H.W., Wyte M.C., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35 (1983) 1126-1138
19. Haagen L., and Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur. J. Clin. Chem. Clim. Biochem. 30 (1992) 391-395
20. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin. Biochem. 37 (2004) 112-119
21. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin. Biochem. 38 (2005) 1103-1111
22. Kosecik M., Erel O., Sevinc E., and Selek S. Increased oxidative stress in children exposed to passive smoking. Intern. J. Cardiol. 100 (2005) 61-64
23. Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol. 300 (1999) 58-62
24. Zurlo M.G., De Stefano P., Borgna-Pignatti C., Di Palma A., Piga A., Melevendi C., et al. Survival and causes of death in thalassaemia major. Lancet 2 (1989) 27-30
25. Deiana L., Garuti R., Pes G.M., Carru C., Errigo A., Rolleri M., et al. Influence of beta (0)-thalassemia on the phenotypic expression of heterozygous familial hypercholesterolemia: a study of patients with familial hypercholesterolemia from Sardinia. Arterioscler. Thromb Vasc. Biol. 20 (2000) 236-243
26. Steinberg D., and Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 95 (1997) 1062-1071
27. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low-density lipoprotein. J. Clin. Invest. 96 (1995) 2882-2891
28. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical. Biol. Med. 26 (1999) 892-904
29. Aslan M., Kosecik M., Horoz M., Selek S., Celik H., and Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis (2006 (May 6)) 10.1016/j.atherosclerosis.2006.04.007